CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Hyperfine Q3 revenue jumps on higher system sales; net loss narrows

By Reuters News


Overview

  • U.S. portable MRI maker's Q3 revenue rose 73% yr/yr to record high

  • Gross profit and gross margin reached record levels in Q3

  • Operating loss narrowed 19% yr/yr, net loss also declined


Outlook

  • Company maintains 2026 revenue guidance at $20 mln to $22 mln

  • Company maintains 2026 net cash burn guidance at $26 mln to $28 mln

  • Company plans to file new $150 mln shelf registration statement before November 2026 expiration


Result Drivers

  • HIGHER SYSTEM SALES - Co said Q3 revenue growth was driven by a 75% increase in commercial Swoop system sales yr/yr

  • INTERNATIONAL EXPANSION - Co cited new launches and distributor agreements in Europe, UK, Kuwait and UAE as supporting sales growth

  • PRODUCT UPGRADES - Co said new software features and regulatory clearances enhanced product capabilities


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Loss Per Share

$0.06

Q3 Net Loss

$5.98 mln

Q3 Operating Expenses

$10.64 mln

Q3 Operating Income

-$7.26 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for Hyperfine, Inc. is $2.00, about 178% above its November 6 closing price of $0.72


Reuters Recommended Reads

  • Nov 9 - Quanterix Q3 revenue rises 6.3% sequentially

  • Nov 9 - Ionis Pharmaceuticals Q3 revenue rises 55%

  • Nov 9 - Israel's Kamada Q3 revenue up 11%, raises forecast


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.